Gilead Sciences Inc (NASDAQ: GILD) has reported E.P.S. of $1.43 for its fourth fiscal quarter (ending December 31) versus $1.15 for the same period a year ago — an increase of 24%. However, this performance was $-0.26 short of the consensus estimate of $1.70. E.P.S. were $0.38 for the latest four quarters through December 31 versus $4.54 for the same period a year ago — a decline of -92%.
Recent Price Action
On 2/11/25, Gilead Sciences Inc (NASDAQ: GILD) stock rose modestly by 0.7%, closing at $96.14. Trading volume in this advance was normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -2.3% during the last week.
Current PriceTarget Research Rating
Gilead Sciences has a current Value Trend Rating of C (High Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Gilead Sciences has a slightly negative Appreciation Score of 34 but a good Power Rating of 83, producing the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment